Patients vaccinated for COVID-19 with pre-existing atopic dermatitis (AD) were not found to be at a greater risk of adverse events (AEs) compared to patients without AD, according to data presented at the 2022 AAD annual meeting.

“Despite receiving Emergency Use Authorization, questions surrounding the use of mRNA-1273, BNT162b2, and Ad26.COV.2.S COVID-19 remain,” wrote researchers. “Clinical trials have demonstrated its safety and efficacy among healthy human subjects; however, data on patients with underlying chronic disease remains scant as these patient populations were excluded from these trials.”

According to the study authors, in order to examine the safety and efficacy of COVID-19 vaccination among AD patients, a retrospective cohort study was conducted using the TriNetX research network.

Using ICD-10 codes, the research team identified vaccinated patients with and without pre-existing AD. The study participants were put into balanced cohorts by demographics and comorbidities based on 1:1 propensity score matching.

“Incidence of immediate anaphylaxis along with special adverse events, breakthrough COVID-19 infection, and all-cause hospitalization were compared after 30 and 60 days.”

The study authors identified 10,504 patients for the study. According to the findings, patients with pre-existing AD, after 60 days of receiving the COVID-19 vaccine, did not have significantly different risk in adverse outcomes.

“However, AD patients who were prescribed corticosteroids or anti-inflammatory therapy within 1-year of being vaccinated were at higher risk of all-cause hospitalization after 60 days (aRR [95% Confidence Interval]) = (2.9 [1.42,5.93]),” the authors noted.

Finally, the other outcomes of the study that were assessed remained statistically similar between each cohort.

Reference:

Pakhchanian H, Raiker R, Wolf M, Trotter S. Examining the Safety and Efficacy of COVID-19 Vaccination among Atopic Dermatitis Patients. Presented at: AAD Annual Meeting; March 25-28, 2022; Boston, MA.